Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
62.72%
Operating Margin
56.38%
Net Margin
5.81%
Efficiency Metrics
Revenue per Expense Ratio
2.35
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
56.98%
Income Tax Rate
0.00%
EPS
1.2100000000
Balance Sheet Analysis
Current Ratio
4.19
Cash Ratio
2.11
Working Capital
$2.43B
Debt to Equity
2.82
Debt to Assets
63.88%
Equity Ratio
22.61%
Cash Flow Analysis
Operating Cash Flow Ratio
39.76%
Free Cash Flow Ratio
24.96%
CapEx to Revenue
14.80%
Dividends Paid
$687.81M
Stock Buybacks
No buybacks
Total Shareholder Returns
$687.81M
Cash Position Change
118.86%
Key Takeaways (2023 FY)
Increased dividend payments by 0.10%
Detailed Growth Metrics
Core Performance
Revenue
5.31%
Net Income
-67.40%
EPS
-67.47%
Operating Income
80.91%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
26.77%
Operating Cash Flow
1.49%
Free Cash Flow
47.18%
Balance Sheet Health
Assets
7.51%
Debt
13.14%
Book Value per Share
-2.42%
Inventory
0.00%
Shareholder Returns
Dividends per Share
0.10%
Shares Outstanding
0.30%
Long Term Trends
3Y Revenue/Share
17.03%
5Y Revenue/Share
18.35%
3Y Dividend/Share
-1.28%
5Y Dividend/Share
14.98%